Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Biopharma Stocks in Play - ANEW MEDICAL, INC. (NASDAQ: WENA) Gains Triple Digits on Patent News


June 26, 2024 ( Newswire) (, a go-to platform for big investing ideas, including biotech and pharma stocks reports on trading and news for ANEW MEDICAL, INC. (NASDAQ: WENA), a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics.

The stock has had massive gains for investors today, trading at $3.5498, up 1.8998, rising over 115.% with a day's high of $5.11 for even bigger gains during the trading session. Volume is over 85 million shares at the time of the report versus an average trading volume of just over 200,000 shares.

ANEW MEDICAL, announced that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW's secreted Clothe gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

This key intellectual property asset was licensed on an exclusive worldwide basis by ANEW from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain. On March 4, 2024, the Company previously announced patent approval in China (CN108289933B) and is now approved in Hong Kong (HK1259628A1) as well. ANEW plans to begin product development and expand their intellectual property portfolios into the Asian markets beginning in 2024.

Dr. Joseph Sinkule, Founder and CEO of ANEW MEDICAL, commented: "We feel strongly about the significant potential of this therapy and have taken meticulous steps to protect and expand our licensed intellectual property in major global markets. These assets play a vital role in our international product development efforts for neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and ALS (Lou Gehrig's disease). We believe our secreted Klotho RNA splice variant ("s-KL") programs for cell and gene therapy, along with the related protein and genomics diagnostic programs, represent a groundbreaking approach to identifying and treating these devastating diseases."

Dr. Sinkule, continues: "There are two proteins transcribed from the human Klotho gene, s-KL is the RNA splice variant made from the gene. It differs from the full-length Klotho protein transcribed from the gene as it is made by cells primarily in the kidneys and controls phosphate and calcium ion homeostasis in the body. Our studies show that s-KL protein is made predominantly by cells in the human brain and is extremely important in brain function and in the maintenance of normal neurologic function throughout the central nervous system (CNS) and peripheral nervous system. As we advance the program, ANEW will explore diagnostics and therapeutics utilizing the s-KL protein and its interactions with other human proteins and 'genes of interest.' We will also pursue other medical product development and commercial opportunities."

Recent news

Research more Biotech stocks with free stock directory

About - Big Investing Ideas is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: More disclaimer and disclosure info Learn more about publishing your news release and our other news services on the newswire Global investors must adhere to regulations of each country. Please read privacy policy:

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook

Follow us on YouTube

Sign up for free stock news alerts at


800 665 0411 - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on